MedTrace Logo

Application of Megavoltage Imaging to Reduce Artifact After Seed Implants

NCT01810627 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2017-09-26

No results posted yet for this study

Summary

This is a non-randomized study to evaluate the utility of MVCT as a quality assurance measure in patients treated with interstitial permanent seed implants for low and intermediate risk prostate cancer. All patients will received the same standard of care treatment but will receive an additinoal CT image of the prostate.

Conditions

Interventions

RADIATION

MVCT

Patients will receive an additional MVCT scan at their one month follow up visit.

Sponsors & Collaborators

  • William St Clair

    lead OTHER

Principal Investigators

  • William St. Clair, MD · Lucille P. Markey Cancer Center at University of Kentucky

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01810627 on ClinicalTrials.gov